SSTR2 and nasopharyngeal carcinoma: SSTR2 is an Epstein-Barr virus–induced druggable target in nasopharyngeal cancer, and Lechner and others demonstrated the preclinical effectiveness of targeted treatment (Lechner et al., 2021).